Company Overview and News

1
Timken Boosts Inorganic Growth Trajectory With Rollon Buyout

2018-09-20 zacks
The Timken Company (TKR - Free Report) , successfully acquired premium engineered linear motion product manufacturer — Rollon Group, on Sep 18, Financial terms of the transaction have not been disclosed. Share price of the company spiked nearly 2% to $49.50 per share, after news of the acquisition surfaced.
ABB ABLZF TKR LB TRS

6
Auto Sector Powers U.S. Industrial Production: 5 Great Picks

2018-09-17 zacks
Industrial production climbed for the third straight month in August, as robust growth in automobile manufacturing outpaced lackluster production in other sectors. A better-than-expected upsurge in the headline numbers was also backed by an uptick in mining and utilities output.
FLOW CATR CAT LXFR TKR TRS

1
TKR / Timken Co. (THE) null (Current Report)

2018-09-14 sec.gov
Document SECURITIES AND EXCHANGE COMMISSION
TKR

1
TKR / Timken Co. (THE) 8-K (Current Report)

2018-09-06 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
TKR

1
Timken Company's Cone Drive Buyout to Aid Chinese Operations

2018-09-05 zacks
The Timken Company (TKR - Free Report) has announced yesterday that it has completed acquiring Traverse City, MI-based Cone Drive on Sep 1, 2018. Financial terms of the transaction, originally announced on Jul 24, have been kept under wraps. Cone Drive is one of the leading makers of precision drive products. Its manufacturing activities are primarily done in China and the United States. Its product offerings, including H-Fang and Cone drives and many more products, are primarily used in aerial platforms, solar, food & beverage, and automation industries.
AIMC TKR TRS

1
TKR / Timken Co. (THE) 424B5 (Prospectus)

2018-08-23 sec.gov
424B5 Table of Contents CALCULATION OF REGISTRATION FEE
TKR

1
TKR / Timken Co. (THE) FWP

2018-08-22 sec.gov
FWP Filed Pursuant to Rule 433 Registration No. 333-226469 The Timken Company $400,000,000 4.500% Senior Notes due 2028
TKR

1
TKR / Timken Co. (THE) 424B5 (Prospectus)

2018-08-22 sec.gov
424B5 Table of Contents The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to the notes has become effective under the Securities Act of 1933, as amended. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and we are not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.
TKR

1
TKR / Timken Co. (THE) FORM S-3ASR

2018-08-01 sec.gov
Form S-3ASR Table of Contents As filed with the Securities and Exchange Commission on August 1, 2018 Registration No. 333-
TKR

1
The Timken (TKR) Q2 2018 Results - Earnings Call Transcript

2018-07-31 seekingalpha
Good morning. My name is Celestina, and I'll be your conference operator today. As a reminder, this call is being recorded. At this time, I'd like to welcome everyone to The Timken Second Quarter's Earnings Release Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session. Thank you.
ABCBEARS TKR 505665

1
Timken Co. 2018 Q2 - Results - Earnings Call Slides

2018-07-31 seekingalpha
The following slide deck was published by Timken Co. in conjunction with their 2018 Q2 earnings call.
TKR

1
TKR / Timken Co. (THE) 8-K (Current Report)

2018-07-31 sec.gov
Document SECURITIES AND EXCHANGE COMMISSION
TKR

1
TKR / Timken Co. (THE) 8-K (Current Report)

2018-07-27 sec.gov
Document SECURITIES AND EXCHANGE COMMISSION
TKR

1
TKR / Timken Co. (THE) 8-K (Current Report)

2018-07-19 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K
TKR

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to TKR / Timken Co. (THE) on message board site Silicon Investor.

STKR: StockerYale, Inc. STKR: StockerYale, Inc. STKR: StockerYale, Inc. TKR: Timken Co. TKR: Timken Co. TKR: Timken Co.
STKR - Stocker u0026 Yale -New focus : fiberoptics ? STKR - Stocker u0026 Yale -New focus : fiberoptics ? STKR - Stocker u0026 Yale -New focus : fiberoptics ? Takla Star Resources (A.TKR) Takla Star Resources (A.TKR) Takla Star Resources (A.TKR)
TAKLA STAR RESOURCES - TKR/ASE TAKLA STAR RESOURCES - TKR/ASE TAKLA STAR RESOURCES - TKR/ASE TIMKEN CO (NYSE:TKR) TIMKEN CO (NYSE:TKR) TIMKEN CO (NYSE:TKR)
CUSIP: 887389104